HOME >> BIOLOGY >> NEWS
AVAX Technologies receives an additional $3.0 Million (AUD) investment in Australian joint venture from Australian Vaccine Technologies Ltd.

Kansas City, MO, April 6, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced that its Australian joint venture, AVAX Australia Pty. Ltd. has received an additional $3.0 million (AUD) investment from Neptunus International Holdings Limited (NIHL), which was recently renamed Australian Vaccine Technologies Ltd. (AVT). AVAX Australia holds the rights to manufacture and market AVAX Technologies' autologous cancer vaccine (AC Vaccine™) for melanoma, M-Vax™, in Australia and has similar rights in New Zealand. M-Vax is AVAX's lead cancer vaccine and is currently being evaluated in the U.S. in a multicenter pivotal registration trial for Stage III melanoma and in a Phase 2 trial for Stage IV melanoma.

Under the joint venture agreement, AVAX Australia has now received a total of $7.0 million (AUD) from AVT for a 35% interest in the joint venture entity. AVT also has the option to purchase an additional 15% interest for $3.0 million (AUD). Under the terms of the agreement, AVAX Technologies has been granted an option to purchase common stock equivalent to 5% of AVT's fully diluted shares. AVT began trading on the Australian Stock Exchange (ASX) under the symbol "AVT" on March 10, 2000.

Jeffrey M. Jonas, M.D., President and CEO of AVAX Technologies, Inc., stated, "We are very pleased to see AVT increasing their investment in our promising joint venture in Australia. This additional capital investment represents their enthusiasm for the potential of our product and our marketing strategy. We continue to believe that the Australian market allows us to truly demonstrate the validity of our business model and our ability to effectively market individualized product."

In 1999, AVAX announced that it had received notice from Australia's Therapeutic Goods Administration (TGA) that M-Vax may be made available for commercial sale, subject only to licensure of a manufacturing facility. M-Vax, a therapeutic cancer vacc
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext. 34
AVAX Technologies, Inc.
5-Apr-2000


Page: 1 2

Related biology news :

1. Regeneration Technologies introduces advancements at AAOS
2. Palatin Technologies PT-141 increases sexual behavior in female animals
3. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
4. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
5. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
6. AVAX Technologies AC Vaccine™ improves relapse-free survival
7. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
8. First International Congress on Telehealth and Multimedia Technologies Story Ideas
9. Technologies Track, Map Fish Behavior
10. USGS Contributions Enhance Public Health Research, Scientists Showcase Technologies At San Diego Meeting
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Stay on top of current hot topics ... industries. Access to all webinars is free, so be sure to register today to ... http://www.xtalks.com to check out our upcoming webinars, or click below to learn ...
(Date:12/20/2018)... ... December 20, 2018 , ... Human ... the completion of a new usability/observation room. This addition will help meet the ... devices and drug delivery devices/combination products are safe and easy to use when ...
(Date:12/18/2018)... ... December 18, 2018 , ... ... cancers and other serious diseases, today announced the publication of an early feasibility ... treatment of rGBM. , The publication of the study, An Early Feasibility ...
Breaking Biology News(10 mins):
(Date:12/13/2018)... ... December 11, 2018 , ... Researchers at Worcester ... to quickly detect Clostridium difficile (C. diff), a dangerous and sometimes fatal gastrointestinal ... that can be used onsite in doctor’s offices and nursing homes, providing results ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... includes food (human) ingredient. This has been part of their strategic plan and ... Plan and certification creates custom fermentation opportunities for MDG within the $44 Billion ...
(Date:12/5/2018)... ... December 05, 2018 , ... The incredible life story of former ... the European Parliament by Carlos Moedas, the European Commissioner for Research and Innovation. ... in Our Daily Lives, Commissioner Moedas spoke at length of Yousef’s life and journey, ...
(Date:11/29/2018)... Utah (PRWEB) , ... November 29, 2018 , ... RAGS, ... was led by Kickstart Seed Fund, with participation from existing investor and board member ... and Davis Smith of Cotopaxi. The additional funding will enable the company to accelerate ...
Breaking Biology Technology:
Cached News: